The identification of new effective therapeutic options for non-small-cell lung cancer
(NSCLC) represents a crucial challenge in oncology. Recent studies indicate that cancer …

Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults, and
despite advances in neuro-oncology, the prognosis for patients remains dismal. The signal …

Intracellular therapeutic targets that define tumor immunosuppression in both tumor cells
and T cells remain intractable. Here, we have shown that administration of a covalently …

STAT3 signaling has been shown to regulate cellular function and cytokine production in the
tumor microenvironment (TME). Within the head and neck squamous cell carcinoma …

Cancer cells are characterized by the aberrant activation of signaling pathways governing
proliferation, survival, angiogenesis, migration and immune evasion. These processes are …

Aims Despite extensive efforts to find new treatments, chemotherapy is still one of the first
and foremost choices for cancer treatment. The main problems of using these drugs are the …

Simple Summary Activated STAT3 is an essential factor in cancer development; therefore,
blocking STAT3 may be of therapeutic benefit in multiple cancer types. Thanks to recent …

The transcription factor NF-κB is an attractive target for cancer therapy due to its over-
activation in all tumours; however, NF-κB inhibitors developed in the past decades rarely …

Objective Lung cancer is the leading cause of cancer death in both men and women. Non-
small cell lung cancer (NSCLC) has an overall 5-year survival rate of 15%. While aberrant …

Malignant tumors are often associated with an immunosuppressive tumor microenvironment
(TME), rendering most of them resistant to standard-of-care immune checkpoint inhibitors …